GW prices Sativex for MS pain

GW Pharmaceuticals wasted no time preparing to launch its newly-approved Sativex for MS patients. The UK developer says that it will sell the cannabis-based pain therapy for $14 a day. The Wall Street Journal notes that the approval in Britain should also be an encouragement to developers in the country, which have faced some hard times recently. GW spent 11 years developing Sativex and has high hopes for an eventual U.S. approval for cancer pain. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.